Although 2.46 million new instances of STIs were reported, the last year saw a significant drop in cases of gonorrhea and primary and secondary syphilis — primarily driven by the LGBTQ+ community.

AstraZeneca and Amgen announced that a Phase 3 trial of Tezspire (tezepelumab) showed a statistically significant and ...

Rates of sexually transmitted infections (STIs) are slowing after decades of growth in the U.S., according to the latest ...